K Pharma (4896) · RiskRestated
Infection and Safety Risks Arising from Human-Derived Raw Materials
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Infection and Product Safety Risks Associated with Cell- and Animal-Derived MaterialsA theme 5 companies write about · 5 as a headwind · 0 as a tailwind
3 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Safety risks are considered to exist because the risk of infection arising from the characteristics of the raw materials cannot be completely eliminated.」
The company reiterates the infection and safety risks associated with regenerative medicine products using human-derived cells and tissues as raw materials. - FY2024RestatedAnnual report
「Safety risks are considered to exist because the risk of infection arising from the characteristics of the raw materials cannot be completely eliminated.」
The company describes infection and safety risks for regenerative medicine products using human cells and tissues as raw materials, together with responses including preclinical and clinical evaluation. - FY2023First statedAnnual report
「Safety risks are considered to exist because the risk of infection arising from the human cells and tissues used cannot be completely eliminated.」
The company identifies infection risks arising from human cells and tissues used in regenerative medicine products and cites safety evaluations and supply-chain management as responses.